Recent advances in the treatment of heart failure

Circulation Journal

Volumn 66, Issue 2, 2002, Pages 117-121

  Patel, Ayan R ^a   Konstam, Marvin A ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Heart failure therapy; Neurohormones; Resynchronization therapy

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; INOTROPIC AGENT; LOSARTAN; METOPROLOL; MILRINONE; NESIRITIDE; NEUROHORMONE; SPIRONOLACTONE; VALSARTAN; VASOPEPTIDASE INHIBITOR; VASOPRESSIN RECEPTOR ANTAGONIST;

ASSISTED CIRCULATION; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DEVICE; DRUG INDICATION; DRUG TOLERABILITY; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; LUNG WEDGE PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESYNCHRONIZATION THERAPY; REVIEW; TREATMENT OUTCOME; VASOCONSTRICTION; WALKING;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOMYOPATHY, DILATED; ELECTRIC COUNTERSHOCK; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 0036238401     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.66.117     Document Type: Review

References (28)

1. Evidence of improving prognosis in heart failure: Trends in case fatality in 66,547 patients hospitalized between 1986 and 1995
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
3. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
4. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
5. Bradykinin antagonism inhibits antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis
6. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial (the Losartan Heart Failure Survival Study) ELITE II
7. Effect of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: The Valsartan Heart Failure Trial (Val-HeFT)
8. Candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM): Rationale and design
9. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
10. The cardiac insufficiency bisoprolol study II (CIBIS II): A randomised trial
11. Effect of carvedilol on survival in severe chronic heart failure
12. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
13. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial
14. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacologic approaches
15. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
16. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end diastolic pressure in patients with symptomatic left ventricular dysfunction
17. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
18. Intravenous nesiritide, a natriuretic peptide in the treatment of decompensated congestive heart failure
19. Results of the VMAC trial: Vasodilation in the management of acute congestive heart failure
20. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay
21. Multicenter InSync Randomized Clinical Evaluation (MIRACLE): Results of a randomized, double-blind, controlled trial to assess cardiac resynchronization therapy in heart failure patients
22. The REMATCH trial: Rationale, design, and end points: Randomized evaluation of mechanical assistance for the treatment of congestive heart failure
23. Future directions of cardiac assistance
24. A prospective, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of tezosentan in patients with acute decompensated heart failure (RITZ 2)
25. Effects of enrasentan, a nonselective endothelin receptor antagonist, in Class II to III heart failure: Results of the Enrasentan Cooperative Randomized (ENCOR) evaluation
26. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
27. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure
28. Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure: A randomized, double-blind trial